Also, the use of DSP30 and IL‐2 mitotic stimuli at low levels of neoplasia (less than 10%) increases the ability to diagnose abnormalities, while the lipopolysaccharide (LPS) stimulator does not have this ability at a low level.12 The gene discussed is IL2; the disease is neoplasm.